Log In
Print
BCIQ
Print
Print this Print this
 

Votrient, pazopanib

Also known as: formerly Armala, GW786034

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBroad-spectrum inhibitor of VEGF and other tyrosine kinases
Molecular Target Vascular endothelial growth factor (VEGF) receptor 1 (FLT1) (VEGFR-1) ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionVascular endothelial growth factor (VEGF) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$16,000.0M

$14,500.0M

$1,500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today